Trial Outcomes & Findings for Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control (NCT NCT04080128)

NCT ID: NCT04080128

Last Updated: 2026-05-06

Results Overview

test the hypothesis that less ipRGC activity (cells in the back of the eye as measured by blue light-driven inputs to the pupil response - measured by the blue decay coefficient) as measured at the Baseline BLINK 2 is associated with greater axial elongation (eye growth) over three years The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.

Recruitment status

COMPLETED

Target enrollment

248 participants

Primary outcome timeframe

Three years

Results posted on

2026-05-06

Participant Flow

Unit of analysis: Eyes

Participant milestones

Participant milestones
Measure
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: Single Vision/Baseline to Year 2:+2.50 D Multifocal/Year 2 to 3: Single Vision
Participants assigned to single vision contact lens (SCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Overall Study
STARTED
78 156
84 168
86 172
Overall Study
1 year
76 152
79 158
86 172
Overall Study
2 years
74 148
81 162
86 172
Overall Study
3 years
72 144
77 154
86 172
Overall Study
COMPLETED
72 144
77 154
86 172
Overall Study
NOT COMPLETED
6 12
7 14
0 0

Reasons for withdrawal

Reasons for withdrawal
Measure
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: Single Vision/Baseline to Year 2:+2.50 D Multifocal/Year 2 to 3: Single Vision
Participants assigned to single vision contact lens (SCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Overall Study
Lost to Follow-up
3
4
0
Overall Study
Withdrawal by Subject
3
3
0

Baseline Characteristics

Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
BLINK RCT Assignment (NCT02255474): +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: SVLs
n=78 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment (NCT02255474): +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: SVLs
n=84 Participants
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT (NCT02255474): SVLs/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Participants
Participants assigned to Single Vision CL group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Total
n=248 Participants
Total of all reporting groups
Age, Continuous
14.9 years
n=54 Participants
14.9 years
n=60 Participants
15.1 years
n=114 Participants
15 years
n=480 Participants
Sex: Female, Male
Female
51 Participants
n=54 Participants
40 Participants
n=60 Participants
55 Participants
n=114 Participants
146 Participants
n=480 Participants
Sex: Female, Male
Male
27 Participants
n=54 Participants
44 Participants
n=60 Participants
31 Participants
n=114 Participants
102 Participants
n=480 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
23 Participants
n=54 Participants
21 Participants
n=60 Participants
22 Participants
n=114 Participants
66 Participants
n=480 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
54 Participants
n=54 Participants
62 Participants
n=60 Participants
63 Participants
n=114 Participants
179 Participants
n=480 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=54 Participants
1 Participants
n=60 Participants
1 Participants
n=114 Participants
3 Participants
n=480 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants
n=54 Participants
1 Participants
n=60 Participants
1 Participants
n=114 Participants
5 Participants
n=480 Participants
Race (NIH/OMB)
Asian
7 Participants
n=54 Participants
7 Participants
n=60 Participants
8 Participants
n=114 Participants
22 Participants
n=480 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=54 Participants
0 Participants
n=60 Participants
0 Participants
n=114 Participants
1 Participants
n=480 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=54 Participants
4 Participants
n=60 Participants
13 Participants
n=114 Participants
21 Participants
n=480 Participants
Race (NIH/OMB)
White
53 Participants
n=54 Participants
64 Participants
n=60 Participants
53 Participants
n=114 Participants
170 Participants
n=480 Participants
Race (NIH/OMB)
More than one race
9 Participants
n=54 Participants
7 Participants
n=60 Participants
10 Participants
n=114 Participants
26 Participants
n=480 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=54 Participants
1 Participants
n=60 Participants
1 Participants
n=114 Participants
3 Participants
n=480 Participants
Region of Enrollment
United States
78 participants
n=54 Participants
84 participants
n=60 Participants
86 participants
n=114 Participants
248 participants
n=480 Participants
Spherical equivalent (SEQ)
-2.97 Diopters
STANDARD_DEVIATION 1.19 • n=54 Participants
-3.64 Diopters
STANDARD_DEVIATION 1.64 • n=60 Participants
-3.70 Diopters
STANDARD_DEVIATION 1.21 • n=114 Participants
-3.45 Diopters
STANDARD_DEVIATION 1.40 • n=480 Participants
Axial length (AL)
24.86 mm
STANDARD_DEVIATION 0.81 • n=54 Participants
25.35 mm
STANDARD_DEVIATION 1.07 • n=60 Participants
25.23 mm
STANDARD_DEVIATION 0.89 • n=114 Participants
25.16 mm
STANDARD_DEVIATION 0.95 • n=480 Participants

PRIMARY outcome

Timeframe: Three years

Population: Axial length average over right and left eye

test the hypothesis that thinner subfoveal choroidal thickness (a layer of blood vessels) is associated with the outcome of greater axial elongation (eye growth) The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=234 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
The Statistical Correlation Between Three-year Change in Choroidal Thickness and Three-year Change in Axial Length
0.18 mm axial length
Standard Deviation 0.19

PRIMARY outcome

Timeframe: Three years

Population: Axial length average over right and left eye

test the hypothesis that less ipRGC activity (cells in the back of the eye as measured by blue light-driven inputs to the pupil response - measured by the blue decay coefficient) as measured at the Baseline BLINK 2 is associated with greater axial elongation (eye growth) over three years The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
The Statistical Correlation Between iPRGC Activity at BLINK2 Baseline and Three-year Change in Axial Length
0.18 mm axial length
Standard Deviation 0.18

PRIMARY outcome

Timeframe: Three years

Population: Axial length measured as the average of the right and left eye.

test the hypothesis that exposure to light levels over 1000 lux as measured at the Baseline BLINK2 visit is associated with less axial elongation (eye growth) over three years The hypothesis relates to the two years of multifocal contact lens wear and one year of single vision contact lens wear. As such, it uses the entire sample which experiences the same contact lens wear in the BLINK2 Study.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
The Statistical Correlation Between Light Levels Measured at Baseline and Three-year Change in Axial Length
0.18 mm axial length
Standard Deviation 0.18

PRIMARY outcome

Timeframe: 3 years

Population: Right eye only

The three-year change from baseline to three years for choroidal thickness.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=234 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Three-year Choroidal Thickness Change
6.12 microns
Standard Deviation 33.73

PRIMARY outcome

Timeframe: Baseline

Population: exposure received by both eyes

Baseline light exposure as measured by minutes at light levels over 1000 lux. Light exposure was monitored using the Actiwatch2 (Phillips Respironics), a light-sensing and logging watch worn on the wrist. Participants wore the device for a 1 week period to monitor environmental light exposure. The illuminance was measured in lux every minute. Data were scrubbed of periods where the watch was not worn or other artifacts. Light levels over 1000 lux were added to determine time outdoors in minutes.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Duration of Exposure to Light Levels Exceeding 1000 Lux at Baseline
51.28 minutes of light exposure over 1000 lux
Standard Deviation 51.87

PRIMARY outcome

Timeframe: Baseline

Population: Right eyes

Baseline iPRGC activity (cells in the back of the eye as measured by blue light-driven inputs to the pupil response - measured by the blue decay coefficient). The Blue Decay Coefficient represents the rate at which the pupil redilates in the dark after exposure to multiple 5-second pulses of red and blue light. The redilation data are fit by an exponential decay function eβt where t is time in seconds and the coefficient β is the natural log of the percent change in pupil diameter per second. Values range from -0.30 to -0.01. More positive values represent slower pupil redilation and are associated with greater, potentially beneficial ipRGC activity.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=230 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Baseline iPRGC Activity
-0.13 unitless
Standard Deviation 0.06

SECONDARY outcome

Timeframe: Baseline

Population: Right eyes of participants. Using method of Anderson and Stuebing. Anderson HA, Stuebing KK. Subjective versus Objective Accommodative Amplitude: Preschool to Presbyopia. Optom Vis Sci 2014;91:1290-301.

Testing the hypothesis that long-term soft bifocal contact lens wear does not alter accommodative amplitude. This hypothesis predicts that at the baseline BLINK2 Study visit, the accommodative amplitude will be similar across the three treatment groups that were randomly assigned at the beginning of the BLINK Study (NCT02255474). Assessed data from the beginning of the BLINK Study up to the BLINK2 Study Baseline Visit approximately 4.7 years, BLINK2 Study Baseline Visit reported

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Accommodative Amplitude
5.76 Diopters
Interval 5.4 to 6.12
5.72 Diopters
Interval 5.34 to 6.11
5.41 Diopters
Interval 5.05 to 5.78

SECONDARY outcome

Timeframe: Baseline

Population: Right eyes analyzed. near point rod with a card containing 2.06 M (20/125 Snellen equivalent) was placed at 33 cm (a 3D accommodative stimulus) in front of the right eye while the contralateral eye was occluded. The participant was encouraged to keep the letters clear until at least five valid readings were obtained. The average spherical equivalent was added to 3 (the accommodative stimulus), so accommodative lag is positive and accommodative lead is negative.

Testing the hypothesis that long-term soft bifocal contact lens wear does not alter accommodative lag. This hypothesis predicts that at the baseline BLINK2 Study visit, the accommodative lag will be similar across the three treatment groups that were randomly assigned at the beginning of the BLINK Study (NCT02255474). Assessed data from the beginning of the BLINK Study up to the BLINK2 Study Baseline Visit approximately 4.7 years, BLINK2 Study Baseline Visit reported.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Lag of Accommodation
1.63 Diopters
Interval 1.5 to 1.75
1.69 Diopters
Interval 1.53 to 1.83
1.77 Diopters
Interval 1.65 to 1.9

SECONDARY outcome

Timeframe: Baseline

Population: The participant focused on a 20/32 letter on the card, and +2.00-D lenses and -2.00 D lenses using flippers. The accommodative facility was recorded as the number of times the participant cleared the letters (flips), divided by two to yield cycles per minute to the nearest 0.5 cycles.

Testing the hypothesis that long-term soft bifocal contact lens wear does not alter accommodative facility. This hypothesis predicts that at the baseline BLINK2 Study visit, the accommodative lag will be similar across the three treatment groups that were randomly assigned at the beginning of the BLINK Study (NCT02255474). Assessed data from the beginning of the BLINK Study up to the BLINK2 Study Baseline Visit approximately 4.7 years, BLINK2 Study Baseline Visit reported.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Participants
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Participants
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Participants
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Accommodative Facility
9.51 cycles/min
Interval 8.72 to 10.3
9.46 cycles/min
Interval 8.63 to 10.29
9.17 cycles/min
Interval 8.38 to 9.97

SECONDARY outcome

Timeframe: Two year change (Baseline to 2-Year visit)

Population: Right and left eyes averaged

Test the hypothesis that wearing +2.50 D multifocal contact lenses slow rather than merely delay myopia progression. This null hypothesis predicts that during the first two years of the BLINK2 Study, when all subjects will wear +2.50 D multifocal contact lenses, axial length elongation at the same rate regardless of original lens assignment (i.e., +2.50 D multifocal lenses, +1.50 D multifocal lenses, SVLs). Alternatively, faster myopia progression in subjects originally fitted with soft bifocal contact lenses compared to single vision contact lenses would indicate a delay in myopia progression rather than a permanent treatment benefit. Measured as the change the baseline BLINK2 visit to the 2 year visit on the IOLMaster which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the exposures before the baseline visit were part of NCT02255474 immediately before this cohort, the original groups were analyzed.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Slowing of Myopia Progression - Axial Length
25.28 mm
Interval 25.07 to 25.5
24.95 mm
Interval 24.71 to 25.18
25.33 mm
Interval 25.09 to 25.57

SECONDARY outcome

Timeframe: One year change (2-year visit to 3-year visit)

Population: Right and left eye averaged

The investigators will test the hypothesis that there is no increase in myopia when switching from +2.50 D multifocal contact lenses to single vision contact lenses in Year 2 of the BLINK2 observational study. This hypothesis predicts that the progression of myopia during the last year of follow-up when all subjects will switch to single vision contact lenses, will be similar to myopia progression during the first two years when all subjects wore multifocal contact lenses. Alternatively, faster progression after switching to single vision contact lens wear indicates a "rebound" of myopia progression. This aim was specifically designed to measure what happened between the 2nd and 3rd annual visit which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the entire cohort was wearing the same contact lens, it uses all participants together.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=248 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Rebound of Progression - Axial Length
0.03 mm
Interval 0.01 to 0.05

SECONDARY outcome

Timeframe: One year change (2-year visit to 3-year visit)

Population: Right and left eye averaged

The investigators will test the hypothesis that there is no increase in myopia, as measured by the change in the spherical equivalent, when switching from +2.50 D multifocal contact lenses to single vision contact lenses in Year 2 of the BLINK2 observational study. This hypothesis predicts that the progression of myopia during the last year of follow-up when all subjects will switch to single vision contact lenses, will be similar to myopia progression during the first two years when all subjects wore multifocal contact lenses. Alternatively, faster progression after switching to single vision contact lens wear indicates a "rebound" of myopia progression. This aim was specifically designed to measure what happened between the 2nd and 3rd annual visit which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the entire cohort was wearing the same contact lens, it uses all participants together.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=248 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Rebound of Progression - Myopia Progression
-0.17 Diopters
Interval -0.22 to -0.12

SECONDARY outcome

Timeframe: Two year change (Baseline visit to 2-year visit)

Population: Right and left eyes averaged

Test the hypothesis that wearing +2.50 D multifocal contact lenses slow rather than merely delay myopia progression. This null hypothesis predicts that during the first two years of the BLINK2 Study, when all subjects will wear +2.50 D multifocal contact lenses, participants will have myopia progression, as measured by spherical equivalent, at the same rate regardless of original lens assignment (i.e., +2.50 D multifocal lenses, +1.50 D multifocal lenses, SVLs). Alternatively, faster myopia progression in those with soft bifocal contact lenses compared to SVLs would indicate a delay in myopia progression rather than a permanent treatment benefit. Measured between Baseline and Year 2 of the BLINK2 Study which is not the entire time frame of the study - as detailed in the specific aims from the funded grant proposal. Because the exposures before the baseline visit were part of NCT02255474 immediately before this cohort, the original groups were analyzed.

Outcome measures

Outcome measures
Measure
BLINK RCT: Single Vision CLs /Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=86 Eyes
Participants assigned to Single Vision CLs group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
BLINK RCT Assignment: +2.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=78 Eyes
Participants assigned to +2.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses.
BLINK RCT Assignment: +1.50 D/Baseline to Year 2: +2.50 D Multifocal/Year 2 to 3: Single Vision CLs
n=84 Eyes
Participants assigned to +1.50 D multifocal contact lens (MCL) group in BLINK Randomized Control Trial/ In BLINK2 Observational Study Baseline to Year 2: +2.50 D/Year 2 to Year 3: Single Vision Contact Lenses
Slowing of Myopia Progression - Myopia Progression
-3.87 Diopters
Interval -4.19 to -3.54
-3.15 Diopters
Interval -3.51 to -2.8
-3.89 Diopters
Interval -4.25 to -3.53

Adverse Events

+2.50 D/+2.50 D Multifocal Contact Lens

Serious events: 4 serious events
Other events: 47 other events
Deaths: 0 deaths

+1.50 D/+2.50 D Multifocal Contact Lens

Serious events: 0 serious events
Other events: 56 other events
Deaths: 0 deaths

Single Vision Contact Lenses (SVL)/+2.50 D MCL

Serious events: 1 serious events
Other events: 56 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
+2.50 D/+2.50 D Multifocal Contact Lens
n=78 participants at risk
Participants assigned to +2.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
+1.50 D/+2.50 D Multifocal Contact Lens
n=84 participants at risk
Participants assigned to +1.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
Single Vision Contact Lenses (SVL)/+2.50 D MCL
n=86 participants at risk
Participants assigned to SVL group in BLINK, in +2.50 D in BLINK2
Psychiatric disorders
Mental health issue
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Immune system disorders
Allergic reaction: non-ocular
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
Nervous system disorders
Concussion
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
Nervous system disorders
Headache
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.

Other adverse events

Other adverse events
Measure
+2.50 D/+2.50 D Multifocal Contact Lens
n=78 participants at risk
Participants assigned to +2.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
+1.50 D/+2.50 D Multifocal Contact Lens
n=84 participants at risk
Participants assigned to +1.50 D multiple contact lens (MCL) group in BLINK, in +2.50 D in BLINK2
Single Vision Contact Lenses (SVL)/+2.50 D MCL
n=86 participants at risk
Participants assigned to SVL group in BLINK, in +2.50 D in BLINK2
Eye disorders
Allergy: ocular
5.1%
4/78 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
6.0%
5/84 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
8.1%
7/86 • Number of events 7 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
BV/accommodation issue
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Immune system disorders
Allergy: non-ocular
1.3%
1/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
2.4%
2/84 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
3.5%
3/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Contact lens acute red eye
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
General disorders
Uncategorized
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
3.5%
3/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
Nervous system disorders
Concussion
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
2.4%
2/84 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Conjunctivitis
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
3.6%
3/84 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
3.5%
3/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Corneal epithelial defect/erosion
2.6%
2/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Corneal scar, new
2.6%
2/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
9.5%
8/84 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
15.1%
13/86 • Number of events 18 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Dry eye
2.6%
2/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
3.6%
3/84 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Foreign body
2.6%
2/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Giant papillary conjunctivitis
5.1%
4/78 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
2.3%
2/86 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Hordeolum/chalazion
6.4%
5/78 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
4.8%
4/84 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
5.8%
5/86 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Infiltrative keratitis
5.1%
4/78 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
3.6%
3/84 • Number of events 4 • Three years
Adverse events were classified as determined by the Executive Committee.
5.8%
5/86 • Number of events 5 • Three years
Adverse events were classified as determined by the Executive Committee.
Psychiatric disorders
Mental health issue
12.8%
10/78 • Number of events 14 • Three years
Adverse events were classified as determined by the Executive Committee.
8.3%
7/84 • Number of events 8 • Three years
Adverse events were classified as determined by the Executive Committee.
12.8%
11/86 • Number of events 14 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Optic nerve issue
2.6%
2/78 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
Product Issues
Poor contact lens fit
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Possible microbial keratitis
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Retinal issue
9.0%
7/78 • Number of events 7 • Three years
Adverse events were classified as determined by the Executive Committee.
9.5%
8/84 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
12.8%
11/86 • Number of events 14 • Three years
Adverse events were classified as determined by the Executive Committee.
Product Issues
Contact lens solution issue
3.8%
3/78 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
3.6%
3/84 • Number of events 3 • Three years
Adverse events were classified as determined by the Executive Committee.
2.3%
2/86 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Sterile corneal ulcer
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Subconjunctival hemorrhage
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
General disorders
Systemic disease
15.4%
12/78 • Number of events 18 • Three years
Adverse events were classified as determined by the Executive Committee.
17.9%
15/84 • Number of events 21 • Three years
Adverse events were classified as determined by the Executive Committee.
8.1%
7/86 • Number of events 8 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Transient visual disturbance
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/84 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/86 • Three years
Adverse events were classified as determined by the Executive Committee.
General disorders
Trauma: non-ocular
10.3%
8/78 • Number of events 13 • Three years
Adverse events were classified as determined by the Executive Committee.
10.7%
9/84 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
18.6%
16/86 • Number of events 18 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Trauma: ocular
1.3%
1/78 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
2.4%
2/84 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
2.3%
2/86 • Number of events 2 • Three years
Adverse events were classified as determined by the Executive Committee.
Product Issues
Unspecified contact lens issues
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Eye disorders
Visual symptoms - no obvious cause
0.00%
0/78 • Three years
Adverse events were classified as determined by the Executive Committee.
0.00%
0/84 • Three years
Adverse events were classified as determined by the Executive Committee.
1.2%
1/86 • Number of events 1 • Three years
Adverse events were classified as determined by the Executive Committee.
Nervous system disorders
Headache
10.3%
8/78 • Number of events 9 • Three years
Adverse events were classified as determined by the Executive Committee.
11.9%
10/84 • Number of events 11 • Three years
Adverse events were classified as determined by the Executive Committee.
5.8%
5/86 • Number of events 6 • Three years
Adverse events were classified as determined by the Executive Committee.

Additional Information

Dr. Jeffrey Walline

The Ohio State University

Phone: 614-247-6840

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place